{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T04:35:06Z","timestamp":1775622906283,"version":"3.50.1"},"reference-count":74,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,11,28]],"date-time":"2023-11-28T00:00:00Z","timestamp":1701129600000},"content-version":"vor","delay-in-days":27,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","seminarsinnephrology.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Nephrology"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1016\/j.semnephrol.2023.151480","type":"journal-article","created":{"date-parts":[[2024,1,9]],"date-time":"2024-01-09T10:12:46Z","timestamp":1704795166000},"page":"151480","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Lipid and Bone Effects of Heparin Use During Hemodialysis"],"prefix":"10.1016","volume":"43","author":[{"given":"Bernd","family":"Stegmayr","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li","family":"Zuo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ward","family":"Zadora","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.semnephrol.2023.151480_bib0001","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1093\/ndt\/15.7.1086","article-title":"Practical haemodialysis began with cellophane and heparin: The crucial role of William Thalhimer (1884-1961)","volume":"15","author":"Cameron","year":"2000","journal-title":"Nephrol Dial Transplant."},{"key":"10.1016\/j.semnephrol.2023.151480_bib0002","series-title":"Pharmacology","first-page":"202","article-title":"Anticoagulants and antiplatelet agents. VI. Parenteral anticoagulants","author":"Vogel Anderson","year":"2023"},{"issue":"7","key":"10.1016\/j.semnephrol.2023.151480_bib0003","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1161\/hq0701.093686","article-title":"Mechanism of action and pharmacology of unfractionated heparin","volume":"21","author":"Hirsh","year":"2001","journal-title":"Arterioscler Thromb Vasc Biol."},{"issue":"9","key":"10.1016\/j.semnephrol.2023.151480_bib0004","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1159\/000518456","article-title":"Dyslipidemia in chronic kidney disease: Contemporary concepts and future therapeutic perspectives","volume":"52","author":"Theofilis","year":"2021","journal-title":"Am J Nephrol."},{"key":"10.1016\/j.semnephrol.2023.151480_bib0005","doi-asserted-by":"crossref","DOI":"10.3389\/fphys.2023.1177829","article-title":"Pathophysiology of bone disease in chronic kidney disease: From basics to renal osteodystrophy and osteoporosis","volume":"14","author":"Aguilar","year":"2023","journal-title":"Front Physiol."},{"issue":"14","key":"10.1016\/j.semnephrol.2023.151480_bib0006","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1056\/NEJMoa0810177","article-title":"Rosuvastatin and cardiovascular events in patients undergoing hemodialysis","volume":"360","author":"Fellstr\u00f6m","year":"2009","journal-title":"N Engl J Med."},{"key":"10.1016\/j.semnephrol.2023.151480_bib0007","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1111\/nep.13457","article-title":"Mineral bone disorders in chronic kidney disease","volume":"23","author":"Hou","year":"2018","journal-title":"Nephrology."},{"issue":"1","key":"10.1016\/j.semnephrol.2023.151480_bib0008","doi-asserted-by":"crossref","DOI":"10.1186\/s12882-019-1527-3","article-title":"Renal Association Clinical Practice Guideline on haemodialysis","volume":"20","author":"Ashby","year":"2019","journal-title":"BMC Nephrol."},{"issue":"4","key":"10.1016\/j.semnephrol.2023.151480_bib0009","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1111\/j.1440-1797.2010.01298.x","article-title":"Review: Anticoagulation for haemodialysis","volume":"15","author":"Suranyi","year":"2010","journal-title":"Nephrology."},{"issue":"7","key":"10.1016\/j.semnephrol.2023.151480_bib0010","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1038\/nrcardio.2017.31","article-title":"Hypertriglyceridaemia and risk of coronary artery disease","volume":"14","author":"Reiner","year":"2017","journal-title":"Nat Rev Cardiol."},{"key":"10.1016\/j.semnephrol.2023.151480_bib0011","series-title":"Biochemistry","first-page":"252","article-title":"Cholesterol, lipoprotein, and steroid metabolism. VI. Plasma lipoproteins","author":"Abali","year":"2022"},{"issue":"2","key":"10.1016\/j.semnephrol.2023.151480_bib0012","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2013-004251","article-title":"Mortality in chronic kidney disease and renal replacement therapy: A population-based cohort study","volume":"4","author":"Neovius","year":"2014","journal-title":"BMJ Open."},{"issue":"10","key":"10.1016\/j.semnephrol.2023.151480_bib0013","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1001750","article-title":"Sex-specific differences in hemodialysis prevalence and practices and the male-to-female mortality rate: The Dialysis Outcomes and Practice Patterns Study (DOPPS)","volume":"11","author":"Hecking","year":"2014","journal-title":"PLoS Med."},{"issue":"8","key":"10.1016\/j.semnephrol.2023.151480_bib0014","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1093\/ndt\/gfw104","article-title":"Dialysis modality and nutritional status are associated with variability of inflammatory markers","volume":"31","author":"Snaedal","year":"2016","journal-title":"Nephrol Dial Transplant."},{"issue":"7","key":"10.1016\/j.semnephrol.2023.151480_bib0015","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1038\/ki.2010.487","article-title":"Protein-energy wasting modifies the association of ghrelin with inflammation, leptin, and mortality in hemodialysis patients","volume":"79","author":"Carrero","year":"2011","journal-title":"Kidney Int."},{"issue":"2","key":"10.1016\/j.semnephrol.2023.151480_bib0016","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1053\/j.jrn.2013.01.001","article-title":"Etiology of the protein-energy wasting syndrome in chronic kidney disease: A consensus statement from the International Society of Renal Nutrition and Metabolism (ISRNM)","volume":"23","author":"Carrero","year":"2013","journal-title":"J Ren Nutr."},{"issue":"3","key":"10.1016\/j.semnephrol.2023.151480_bib0017","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1093\/ajcn\/85.3.695","article-title":"Comparison of nutritional and inflammatory markers in dialysis patients with reduced appetite","volume":"85","author":"Carrero","year":"2007","journal-title":"Am J Clin Nutr."},{"issue":"1","key":"10.1016\/j.semnephrol.2023.151480_bib0018","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1053\/j.ajkd.2014.01.014","article-title":"Recovery time, quality of life, and mortality in hemodialysis patients: The Dialysis Outcomes and Practice Patterns Study (DOPPS)","volume":"64","author":"Rayner","year":"2014","journal-title":"Am J Kidney Dis."},{"issue":"6","key":"10.1016\/j.semnephrol.2023.151480_bib0019","doi-asserted-by":"crossref","DOI":"10.3390\/nu9060548","article-title":"Dialysis procedures alter metabolic conditions","volume":"9","author":"Stegmayr","year":"2017","journal-title":"Nutrients."},{"issue":"1","key":"10.1016\/j.semnephrol.2023.151480_bib0020","first-page":"176","article-title":"Hyperlipidemia in renal failure: Studies of plasma lipoproteins, hepatic triglyceride production, and tissue lipoprotein lipase in a chronically uremic rat model","volume":"91","author":"Bagdade","year":"1978","journal-title":"J Lab Clin Med."},{"issue":"6","key":"10.1016\/j.semnephrol.2023.151480_bib0021","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1111\/j.1525-139X.2009.00661.x","article-title":"Causes of dysregulation of lipid metabolism in chronic renal failure","volume":"22","author":"Vaziri","year":"2009","journal-title":"Semin Dial."},{"issue":"2","key":"10.1016\/j.semnephrol.2023.151480_bib0022","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1007\/s10157-011-0549-3","article-title":"Lipoprotein lipase deficiency in chronic kidney disease is accompanied by down-regulation of endothelial GPIHBP1 expression","volume":"16","author":"Vaziri","year":"2012","journal-title":"Clin Exp Nephrol."},{"issue":"5","key":"10.1016\/j.semnephrol.2023.151480_bib0023","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.3390\/toxins6051505","article-title":"Uremic toxins and lipases in haemodialysis: A process of repeated metabolic starvation","volume":"6","author":"Stegmayr","year":"2014","journal-title":"Toxins (Basel)."},{"issue":"12","key":"10.1016\/j.semnephrol.2023.151480_bib0024","doi-asserted-by":"crossref","DOI":"10.3390\/toxins8120376","article-title":"Modified lipids and lipoproteins in chronic kidney disease: A new class of uremic toxins","volume":"8","author":"Florens","year":"2016","journal-title":"Toxins (Basel)."},{"issue":"1","key":"10.1016\/j.semnephrol.2023.151480_bib0025","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1080\/00365510310000484","article-title":"Lipoprotein lipase during heparin infusion: Lower activity in hemodialysis patients","volume":"63","author":"Nasstrom","year":"2003","journal-title":"Scand J Clin Lab Invest."},{"issue":"4","key":"10.1016\/j.semnephrol.2023.151480_bib0026","doi-asserted-by":"crossref","first-page":"296","DOI":"10.3109\/00365513.2014.882016","article-title":"Lipoprotein lipase activity is favoured by peritoneal dialysis compared to hemodialysis","volume":"74","author":"Mahmood","year":"2014","journal-title":"Scand J Clin Lab Invest."},{"issue":"3","key":"10.1016\/j.semnephrol.2023.151480_bib0027","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1067\/mlc.2001.117666","article-title":"Lipoprotein lipase during continuous heparin infusion: Tissue stores become partially depleted","volume":"138","author":"Nasstrom","year":"2001","journal-title":"J Lab Clin Med."},{"issue":"6","key":"10.1016\/j.semnephrol.2023.151480_bib0028","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1093\/ndt\/gfh774","article-title":"A single bolus of a low molecular weight heparin to patients on haemodialysis depletes lipoprotein lipase stores and retards triglyceride clearing","volume":"20","author":"Nasstrom","year":"2005","journal-title":"Nephrol Dial Transplant."},{"key":"10.1016\/j.semnephrol.2023.151480_bib0030","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/1471-2369-11-33","article-title":"Lipoprotein lipase responds similarly to tinzaparin as to conventional heparin during hemodialysis","volume":"11","author":"Mahmood","year":"2010","journal-title":"BMC Nephrol."},{"issue":"1","key":"10.1016\/j.semnephrol.2023.151480_bib0029","doi-asserted-by":"crossref","first-page":"13","DOI":"10.5301\/ijao.5000252","article-title":"Response of angiopoietin-like proteins 3 and 4 to hemodialysis","volume":"37","author":"Mahmood","year":"2014","journal-title":"Int J Artif Organs."},{"issue":"5","key":"10.1016\/j.semnephrol.2023.151480_bib0031","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1038\/ki.1996.192","article-title":"Increased lipase inhibition in uremia: identification of pre-beta-HDL as a major inhibitor in normal and uremic plasma","volume":"49","author":"Cheung","year":"1996","journal-title":"Kidney Int."},{"issue":"4","key":"10.1016\/j.semnephrol.2023.151480_bib0032","doi-asserted-by":"crossref","DOI":"10.1098\/rsob.150272","article-title":"The ANGPTL3-4-8 model, a molecular mechanism for triglyceride trafficking","volume":"6","author":"Zhang","year":"2016","journal-title":"Open Biol."},{"issue":"2","key":"10.1016\/j.semnephrol.2023.151480_bib0033","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1055\/s-0030-1267917","article-title":"Serum levels of the adipokine fasting-induced adipose factor\/angiopoietin-like protein 4 depend on renal function","volume":"43","author":"Baranowski","year":"2011","journal-title":"Horm Metab Res."},{"issue":"12","key":"10.1016\/j.semnephrol.2023.151480_bib0034","doi-asserted-by":"crossref","first-page":"E2510","DOI":"10.1210\/jc.2013-4349","article-title":"Circulating angiopoietin-like protein 8 is independently associated with fasting plasma glucose and type 2 diabetes mellitus","volume":"99","author":"Ebert","year":"2014","journal-title":"J Clin Endocrinol Metab."},{"issue":"8","key":"10.1016\/j.semnephrol.2023.151480_bib0035","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1097\/00019501-200512000-00003","article-title":"Abnormalities of coagulation, platelet function, and fibrinolysis associated with syndromes of insulin resistance","volume":"16","author":"Schneider","year":"2005","journal-title":"Coron Artery Dis."},{"issue":"3","key":"10.1016\/j.semnephrol.2023.151480_bib0036","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1053\/j.ajkd.2015.09.027","article-title":"Role of the gut microbiome in uremia: A potential therapeutic target","volume":"67","author":"Ramezani","year":"2016","journal-title":"Am J Kidney Dis."},{"issue":"4","key":"10.1016\/j.semnephrol.2023.151480_bib0037","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1097\/01.mco.0000172590.32564.b9","article-title":"Carbohydrate metabolism in uraemia","volume":"8","author":"Rigalleau","year":"2005","journal-title":"Curr Opin Clin Nutr Metab Care."},{"issue":"5","key":"10.1016\/j.semnephrol.2023.151480_bib0038","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1136\/jcp.2007.048868","article-title":"The cell biology of bone metabolism","volume":"61","author":"Datta","year":"2008","journal-title":"J Clin Pathol."},{"issue":"10","key":"10.1016\/j.semnephrol.2023.151480_bib0039","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1093\/rheumatology\/kev410","article-title":"Novel biological markers of bone: From bone metabolism to bone physiology","volume":"55","author":"Chapurlat","year":"2016","journal-title":"Rheumatology (Oxford)."},{"issue":"1","key":"10.1016\/j.semnephrol.2023.151480_bib0040","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1186\/1479-5876-11-201","article-title":"The clinical utility of bone marker measurements in osteoporosis","volume":"11","author":"Wheater","year":"2013","journal-title":"J Transl Med."},{"issue":"suppl 1","key":"10.1016\/j.semnephrol.2023.151480_bib0041","doi-asserted-by":"crossref","first-page":"S23","DOI":"10.2215\/CJN.05910809","article-title":"Calcium metabolism in health and disease","volume":"5","author":"Peacock","year":"2010","journal-title":"Clin J Am Soc Nephrol."},{"issue":"8","key":"10.1016\/j.semnephrol.2023.151480_bib0042","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.1016\/j.ekir.2021.05.012","article-title":"Phosphate balance and CKD\u2013mineral bone disease","volume":"6","author":"Sprague","year":"2021","journal-title":"Kidney Int Rep."},{"key":"10.1016\/j.semnephrol.2023.151480_bib0043","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1001\/jama.1965.03090020005001","article-title":"Heparin osteoporosis","volume":"193","author":"Griffith","year":"1965","journal-title":"JAMA."},{"issue":"4","key":"10.1016\/j.semnephrol.2023.151480_bib0044","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1182\/blood.V88.4.1314.bloodjournal8841314","article-title":"Histomorphometric analysis of the effects of standard heparin on trabecular bone in vivo","volume":"88","author":"Muir","year":"1996","journal-title":"Blood."},{"issue":"9","key":"10.1016\/j.semnephrol.2023.151480_bib0045","doi-asserted-by":"crossref","first-page":"3236","DOI":"10.1182\/blood.V89.9.3236","article-title":"A histomorphometric comparison of the effects of heparin and low-molecular-weight heparin on cancellous bone in rats","volume":"89","author":"Muir","year":"1997","journal-title":"Blood."},{"issue":"4","key":"10.1016\/j.semnephrol.2023.151480_bib0046","first-page":"451","article-title":"Effects of enoxaparin on histomorphometric parameters of bones in rats","volume":"56","author":"Folwarczna","year":"2004","journal-title":"Pol J Pharmacol."},{"issue":"3","key":"10.1016\/j.semnephrol.2023.151480_bib0047","first-page":"337","article-title":"Effects of nadroparin on bone histomorphometric parameters in rats","volume":"56","author":"Folwarczna","year":"2004","journal-title":"Pol J Pharmacol."},{"key":"10.1016\/j.semnephrol.2023.151480_bib0048","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.bone.2013.10.010","article-title":"Effects of unfractionated heparin on renal osteodystrophy and vascular calcification in chronic kidney disease rats","volume":"58","author":"Meng","year":"2014","journal-title":"Bone."},{"key":"10.1016\/j.semnephrol.2023.151480_bib0049","first-page":"181","article-title":"A comparative study on effects of low molecular weight heparin and unfractionated heparin on renal osteodystrophy and vascular calcification in rats with chronic kidney disease","volume":"24","author":"Meng","year":"2018","journal-title":"Chin J Osteoporos."},{"issue":"9","key":"10.1016\/j.semnephrol.2023.151480_bib0050","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1007\/s00113-002-0419-2","article-title":"[Influence of unfractionated and low-molecular-weight heparin on bone healing: An animal model]","volume":"105","author":"Kock","year":"2002","journal-title":"Unfallchirurg."},{"issue":"1","key":"10.1016\/j.semnephrol.2023.151480_bib0051","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/s00774-021-01268-5","article-title":"Impaired bone healing by enoxaparin via inhibiting the differentiation of bone marrow mesenchymal stem cells towards osteoblasts","volume":"40","author":"Li","year":"2022","journal-title":"J Bone Miner Metab."},{"key":"10.1016\/j.semnephrol.2023.151480_bib0052","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.bone.2015.04.039","article-title":"Heparin affects human bone marrow stromal cell fate: Promoting osteogenic and reducing adipogenic differentiation and conversion","volume":"78","author":"Simann","year":"2015","journal-title":"Bone."},{"issue":"6","key":"10.1016\/j.semnephrol.2023.151480_bib0053","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1007\/s00132-002-0308-y","article-title":"[Heparin facilities proliferation of human osteoblasts in vitro]","volume":"31","author":"Matziolis","year":"2002","journal-title":"Orthopade."},{"issue":"10","key":"10.1016\/j.semnephrol.2023.151480_bib0054","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1002\/jor.21138","article-title":"Heparanase in primary human osteoblasts","volume":"28","author":"Smith","year":"2010","journal-title":"J Orthop Res."},{"issue":"14","key":"10.1016\/j.semnephrol.2023.151480_bib0055","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1101\/gad.266551.115","article-title":"Fibroblast growth factor signaling in skeletal development and disease","volume":"29","author":"Ornitz","year":"2015","journal-title":"Genes Dev."},{"issue":"1","key":"10.1016\/j.semnephrol.2023.151480_bib0056","doi-asserted-by":"crossref","first-page":"361","DOI":"10.3892\/mmr.2017.6570","article-title":"Effects of unfractionated heparin and rivaroxaban on the expression of heparanase and fibroblast growth factor 2 in human osteoblasts","volume":"16","author":"Xia","year":"2017","journal-title":"Mol Med Rep."},{"issue":"3","key":"10.1016\/j.semnephrol.2023.151480_bib0057","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1177\/107602960200800309","article-title":"Osteoblast growth inhibition by unfractionated heparin and by low molecular weight heparins: An in-vitro investigation","volume":"8","author":"Kock","year":"2002","journal-title":"Clin Appl Thromb Hemost."},{"key":"10.1016\/j.semnephrol.2023.151480_bib0058","doi-asserted-by":"crossref","first-page":"52","DOI":"10.2174\/1874325001105010052","article-title":"Effect of a direct thrombin inhibitor compared with dalteparin and unfractionated heparin on human osteoblasts","volume":"5","author":"Winkler","year":"2011","journal-title":"Open Orthop J."},{"issue":"4","key":"10.1016\/j.semnephrol.2023.151480_bib0059","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1182\/blood.V93.4.1231","article-title":"A histomorphometric evaluation of heparin-induced bone loss after discontinuation of heparin treatment in rats","volume":"93","author":"Shaughnessy","year":"1999","journal-title":"Blood."},{"issue":"5","key":"10.1016\/j.semnephrol.2023.151480_bib0060","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1002\/jcb.20007","article-title":"Low doses and high doses of heparin have different effects on osteoblast-like Saos-2 cells in vitro","volume":"91","author":"Hausser","year":"2004","journal-title":"J Cell Biochem."},{"issue":"4","key":"10.1016\/j.semnephrol.2023.151480_bib0061","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1177\/1076029606293433","article-title":"Cbfa-1 (Runx-2) and osteocalcin expression by human osteoblasts in heparin osteoporosis in vitro","volume":"12","author":"Handschin","year":"2006","journal-title":"Clin Appl Thromb Hemost."},{"issue":"2","key":"10.1016\/j.semnephrol.2023.151480_bib0062","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1002\/bjs.4809","article-title":"Effect of low molecular weight heparin (dalteparin) and fondaparinux (Arixtra) on human osteoblasts in vitro","volume":"92","author":"Handschin","year":"2005","journal-title":"Br J Surg."},{"issue":"3","key":"10.1016\/j.semnephrol.2023.151480_bib0063","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1055\/s-0038-1645074","article-title":"Effects of low molecular weight heparin and unfragmented heparin on induction of osteoporosis in rats","volume":"63","author":"M\u00e4tzsch","year":"1990","journal-title":"Thromb Haemost."},{"issue":"2","key":"10.1016\/j.semnephrol.2023.151480_bib0064","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.bone.2007.04.190","article-title":"Heparin enhances osteoclastic bone resorption by inhibiting osteoprotegerin activity","volume":"41","author":"Irie","year":"2007","journal-title":"Bone."},{"issue":"4","key":"10.1016\/j.semnephrol.2023.151480_bib0065","doi-asserted-by":"crossref","DOI":"10.3390\/ijms17040613","article-title":"Unfractionated heparin promotes osteoclast formation in vitro by inhibiting osteoprotegerin activity","volume":"17","author":"Li","year":"2016","journal-title":"Int J Mol Sci."},{"issue":"3","key":"10.1016\/j.semnephrol.2023.151480_bib0066","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1016\/S0002-9378(94)70299-3","article-title":"A prospective study of heparin-induced osteoporosis in pregnancy using bone densitometry","volume":"170","author":"Barbour","year":"1994","journal-title":"Am J Obstet Gynecol."},{"issue":"4","key":"10.1016\/j.semnephrol.2023.151480_bib0067","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1016\/0002-9378(93)90378-V","article-title":"Osteoporotic fractures and the recurrence of thromboembolism during pregnancy and the puerperium in 184 women undergoing thromboprophylaxis with heparin","volume":"168","author":"Dahlman","year":"1993","journal-title":"Am J Obstet Gynecol."},{"issue":"11","key":"10.1016\/j.semnephrol.2023.151480_bib0068","doi-asserted-by":"crossref","first-page":"2876","DOI":"10.1093\/humrep\/14.11.2876","article-title":"Bone density changes in pregnant women treated with heparin: A prospective, longitudinal study","volume":"14","author":"Backos","year":"1999","journal-title":"Hum Reprod."},{"key":"10.1016\/j.semnephrol.2023.151480_bib0069","first-page":"S131","article-title":"Kinetics of technetium-labeled heparin in hemodialyzed patients","volume":"41","author":"Majdalani","year":"1993","journal-title":"Kidney Int Suppl."},{"issue":"4","key":"10.1016\/j.semnephrol.2023.151480_bib73","doi-asserted-by":"crossref","first-page":"469","DOI":"10.3109\/08860221003675260","article-title":"Risk factors leading to reduced bone mineral density in hemodialysis patients with metabolic syndrome","volume":"32","author":"Binici","year":"2010","journal-title":"Ren Fail"},{"issue":"3","key":"10.1016\/j.semnephrol.2023.151480_bib0070","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1111\/hdi.12854","article-title":"Effect of long-term use of unfractionated or low-molecular-weight heparin on bone mineral density in maintenance hemodialysis patients","volume":"24","author":"Yang","year":"2020","journal-title":"Hemodial Int."},{"issue":"4","key":"10.1016\/j.semnephrol.2023.151480_bib74","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1177\/1076029612463424","article-title":"Effect of unfractionated and low-molecular-weight heparin on OPG, sRANKL, and von Willebrand factor concentrations during hemodialysis","volume":"20","author":"Klejna","year":"2014","journal-title":"Clin Appl Thromb Hemost"},{"issue":"7","key":"10.1016\/j.semnephrol.2023.151480_bib0071","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1177\/039139880102400708","article-title":"Effect of low molecular weight heparin on bone metabolism and hyperlipidemia in patients on maintenance hemodialysis","volume":"24","author":"Lai","year":"2001","journal-title":"Int J Artif Organs."},{"issue":"1","key":"10.1016\/j.semnephrol.2023.151480_bib0072","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1186\/s12882-020-01916-4","article-title":"Osteoporotic fracture rates in chronic hemodialysis and effect of heparin exposure: A retrospective cohort study","volume":"21","author":"Harrak","year":"2020","journal-title":"BMC Nephrol."}],"container-title":["Seminars in Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0270929523001900?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0270929523001900?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,27]],"date-time":"2025-05-27T14:50:47Z","timestamp":1748357447000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0270929523001900"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11]]},"references-count":74,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,11]]}},"alternative-id":["S0270929523001900"],"URL":"https:\/\/doi.org\/10.1016\/j.semnephrol.2023.151480","relation":{},"ISSN":["0270-9295"],"issn-type":[{"value":"0270-9295","type":"print"}],"subject":[],"published":{"date-parts":[[2023,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Lipid and Bone Effects of Heparin Use During Hemodialysis","name":"articletitle","label":"Article Title"},{"value":"Seminars in Nephrology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.semnephrol.2023.151480","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"151480"}}